CY1118928T1 - Αντι-οχ40 αντισωματα και μεθοδοι χρησης τους - Google Patents

Αντι-οχ40 αντισωματα και μεθοδοι χρησης τους

Info

Publication number
CY1118928T1
CY1118928T1 CY20171100363T CY171100363T CY1118928T1 CY 1118928 T1 CY1118928 T1 CY 1118928T1 CY 20171100363 T CY20171100363 T CY 20171100363T CY 171100363 T CY171100363 T CY 171100363T CY 1118928 T1 CY1118928 T1 CY 1118928T1
Authority
CY
Cyprus
Prior art keywords
antibodies
receptor
human antibodies
recombinant human
antibody
Prior art date
Application number
CY20171100363T
Other languages
English (en)
Inventor
Yong-Jun Liu
Kui Shin Voo
Laura Bover
Naoya Tsurushita
J Yun Tso
Shankar Kumar
Original Assignee
Board Of Regents, The University Of Texas System
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Board Of Regents, The University Of Texas System filed Critical Board Of Regents, The University Of Texas System
Publication of CY1118928T1 publication Critical patent/CY1118928T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/74—Inducing cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen

Abstract

Ανθρώπινα αντισώματα, κατά προτίμηση ανασυνδυασμένα ανθρώπινα αντισώματα, αμφότερα ανθρωποποιημένα και χιμαιρικά, τα οποία δεσμεύονται ειδικά με ανθρώπινο ΟΧ40 γνωστοποιούνται. Προτιμητέα αντισώματα έχουν υψηλή συγγένεια για ΟΧ40 υποδοχέα και ενεργοποιούν τον υποδοχέα in vitro και in vivo. Το αντίσωμα μπορεί να είναι ένα πλήρους-μήκους αντίσωμα ή ένα αντιγονοδεσμευτικό τμήμα αυτού. Τα αντισώματα, ή τμήματα αντισωμάτων, είναι χρήσιμα για διαμόρφωση της δραστικότητας του υποδοχέα, π.χ., σε έναν άνθρωπο ο οποίος πάσχει από μία διαταραχή στην οποία η ΟΧ40 δραστικότητα είναι επιβλαβής. Νουκλεϊκά οξέα, φορείς και κύτταρα ξενιστές για έκφραση των ανασυνδυασμένων ανθρώπινων αντισωμάτων παρέχονται, και μέθοδοι σύνθεσης των ανασυνδυασμένων ανθρώπινων αντισωμάτων, επίσης παρέχονται.
CY20171100363T 2010-08-23 2017-03-22 Αντι-οχ40 αντισωματα και μεθοδοι χρησης τους CY1118928T1 (el)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US37599910P 2010-08-23 2010-08-23
US38082710P 2010-09-08 2010-09-08
PCT/US2011/048752 WO2012027328A2 (en) 2010-08-23 2011-08-23 Anti-ox40 antibodies and methods of using the same

Publications (1)

Publication Number Publication Date
CY1118928T1 true CY1118928T1 (el) 2018-01-10

Family

ID=45724011

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20171100363T CY1118928T1 (el) 2010-08-23 2017-03-22 Αντι-οχ40 αντισωματα και μεθοδοι χρησης τους

Country Status (34)

Country Link
US (6) US9006399B2 (el)
EP (2) EP2609118B1 (el)
JP (2) JP5984810B2 (el)
KR (2) KR101704865B1 (el)
CN (2) CN106554417B (el)
AP (1) AP2013006771A0 (el)
AU (1) AU2011293558B2 (el)
BR (2) BR112013004266A8 (el)
CA (1) CA2809089C (el)
CL (3) CL2013000545A1 (el)
CO (1) CO6680693A2 (el)
CR (1) CR20130126A (el)
CY (1) CY1118928T1 (el)
DK (1) DK2609118T3 (el)
DO (1) DOP2013000045A (el)
EA (2) EA029793B1 (el)
ES (2) ES2649155T3 (el)
HK (1) HK1213272A1 (el)
HR (1) HRP20170568T1 (el)
HU (1) HUE031371T2 (el)
IL (2) IL224886A (el)
LT (1) LT2609118T (el)
ME (1) ME02678B (el)
MX (1) MX339964B (el)
MY (1) MY171312A (el)
NZ (3) NZ608033A (el)
PE (2) PE20131403A1 (el)
PL (1) PL2609118T3 (el)
PT (1) PT2609118T (el)
RS (1) RS55952B1 (el)
SG (1) SG187945A1 (el)
SI (1) SI2609118T1 (el)
WO (1) WO2012027328A2 (el)
ZA (1) ZA201301442B (el)

Families Citing this family (174)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY171312A (en) * 2010-08-23 2019-10-08 Univ Texas Anti-ox40 antibodies and methods of using the same
WO2013008171A1 (en) * 2011-07-11 2013-01-17 Glenmark Pharmaceuticals S.A. Antibodies that bind to ox40 and their uses
AU2012299421B2 (en) * 2011-08-23 2016-02-04 Board Of Regents, The University Of Texas System Anti-OX40 antibodies and methods of using the same
GB201116092D0 (en) 2011-09-16 2011-11-02 Bioceros B V Antibodies and uses thereof
EP3508215A3 (en) 2012-12-03 2019-10-02 Bristol-Myers Squibb Company Enhancing anti-cancer activity of immunomodulatory fc fusion proteins
KR101645112B1 (ko) 2013-03-06 2016-08-02 아스트라제네카 아베 표피 성장 인자 수용체의 활성화 돌연변이체 형태의 퀴나졸린 억제제
SG11201507781VA (en) * 2013-03-18 2015-10-29 Biocerox Prod Bv Humanized anti-cd134 (ox40) antibodies and uses thereof
US11273204B2 (en) 2013-08-08 2022-03-15 Cytune Pharma IL-15 and IL-15RAPLHA sushi domain based immunocytokines
SG10201907841UA (en) * 2013-11-22 2019-10-30 Dnatrix Inc Adenovirus expressing immune cell stimulatory receptor agonist(s)
AU2014364606A1 (en) 2013-12-17 2016-07-07 Genentech, Inc. Combination therapy comprising OX40 binding agonists and PD-1 axis binding antagonists
GB201403775D0 (en) 2014-03-04 2014-04-16 Kymab Ltd Antibodies, uses & methods
CN106132439A (zh) * 2014-03-31 2016-11-16 豪夫迈·罗氏有限公司 包含抗血管发生剂和ox40结合激动剂的组合疗法
US10478491B2 (en) 2014-04-03 2019-11-19 Augusta University Research Institute, Inc. Methods for enhancing the efficacy of a tumor-directed immune response
JO3664B1 (ar) 2014-08-19 2020-08-27 Merck Sharp & Dohme أجسام مضادة لـ tigit
MA41044A (fr) 2014-10-08 2017-08-15 Novartis Ag Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer
CU20170052A7 (es) 2014-10-14 2017-11-07 Dana Farber Cancer Inst Inc Moléculas de anticuerpo que se unen a pd-l1
WO2016070051A2 (en) 2014-10-31 2016-05-06 Oncomed Pharmaceuticals, Inc. Combination therapy for treatment of disease
US20160160290A1 (en) 2014-11-03 2016-06-09 Genentech, Inc. Methods and biomarkers for predicting efficacy and evaluation of an ox40 agonist treatment
JP6702991B2 (ja) 2014-11-03 2020-06-03 ジェネンテック， インコーポレイテッド Ｔ細胞免疫サブセットを検出するためのアッセイ及びその使用の方法
RU2017119428A (ru) * 2014-11-06 2018-12-06 Дженентек, Инк. Комбинированная терапия, включающая применение агонистов, связывающихся с ох40, и ингибиторов tigit
SG10201807625PA (en) 2014-11-17 2018-10-30 Genentech Inc Combination therapy comprising ox40 binding agonists and pd-1 axis binding antagonists
MA41414A (fr) 2015-01-28 2017-12-05 Centre Nat Rech Scient Protéines de liaison agonistes d' icos
MA41460A (fr) 2015-02-03 2017-12-12 Oncomed Pharm Inc Agents de liaison à la tnfrsf et leurs utilisations
CN114504652A (zh) * 2015-03-03 2022-05-17 科马布有限公司 抗体、用途和方法
US20180044429A1 (en) 2015-03-09 2018-02-15 Celldex Therapeutics, Inc. Cd27 agonists
CN107709364A (zh) 2015-04-07 2018-02-16 豪夫迈·罗氏有限公司 具有激动剂活性的抗原结合复合体及使用方法
KR20180015650A (ko) * 2015-05-07 2018-02-13 아게누스 인코포레이티드 항-ox40 항체 및 이의 사용 방법
MY188049A (en) 2015-05-29 2021-11-12 Bristol Myers Squibb Co Antibodies against ox40 and uses thereof
SI3317301T1 (sl) 2015-07-29 2021-10-29 Novartis Ag Kombinirane terapije, ki obsegajo molekule protitelesa na LAG-3
WO2017019897A1 (en) 2015-07-29 2017-02-02 Novartis Ag Combination therapies comprising antibody molecules to tim-3
WO2017021911A1 (en) 2015-08-04 2017-02-09 Glaxosmithkline Intellectual Property Development Limited Combination treatments and uses and methods thereof
EP3331917A1 (en) 2015-08-04 2018-06-13 GlaxoSmithKline Intellectual Property Development Limited Combination treatments and uses and methods thereof
RU2018107693A (ru) * 2015-08-04 2019-09-05 Глэксосмитклайн Интеллекчуал Проперти Дивелопмент Лимитед Комбинированные виды лечения и их варианты применения и способы
WO2017021912A1 (en) 2015-08-06 2017-02-09 Glaxosmithkline Intellectual Property Development Limited Combined tlrs modulators with anti ox40 antibodies
TW201716084A (zh) * 2015-08-06 2017-05-16 葛蘭素史克智慧財產發展有限公司 組合物及其用途與治療
EP3331919A1 (en) 2015-08-07 2018-06-13 GlaxoSmithKline Intellectual Property Development Limited Combination therapy comprising anti ctla-4 antibodies
CN115925931A (zh) 2015-08-14 2023-04-07 默沙东公司 抗tigit抗体
MA48579A (fr) 2015-09-01 2020-03-18 Agenus Inc Anticorps anti-pd1 et méthodes d'utilisation de ceux-ci
US20190022092A1 (en) 2015-09-15 2019-01-24 Acerta Pharma B.V. Therapeutic Combinations of a BTK Inhibitor and a GITR Binding Molecule, a 4-1BB Agonist, or an OX40 Agonist
JP7034066B2 (ja) 2015-10-02 2022-03-11 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト 共刺激ｔｎｆ受容体に対する二重特異性抗体
US10624974B2 (en) 2015-10-15 2020-04-21 Dingfu Biotarget Co., Ltd. Anti-OX40 antibody and application thereof
BR112018008891A8 (pt) 2015-11-03 2019-02-26 Janssen Biotech Inc anticorpos que se ligam especificamente a pd-1 e tim-3 e seus usos
GB201520903D0 (en) * 2015-11-26 2016-01-13 Qbd Qs Ip Ltd Purification method
EP4015537A1 (en) * 2015-12-01 2022-06-22 GlaxoSmithKline Intellectual Property Development Limited Combination treatments and uses and methods thereof
CA3007233A1 (en) * 2015-12-02 2017-06-08 Agenus Inc. Antibodies and methods of use thereof
EP3383914A4 (en) * 2015-12-02 2019-10-30 Agenus Inc. ANTI-OX40 ANTIBODIES AND METHODS OF USE
MA52157A (fr) 2015-12-03 2021-02-17 Glaxosmithkline Ip Dev Ltd Dinucléotides cycliques de purine utilisés comme modulateurs de sting
CA3006963A1 (en) * 2015-12-03 2017-06-08 Ludwig Institute For Cancer Research Ltd. Anti-ox40 antibodies and methods of use thereof
WO2017098421A1 (en) 2015-12-08 2017-06-15 Glaxosmithkline Intellectual Property Development Limited Benzothiadiazine compounds
JP2019503349A (ja) 2015-12-17 2019-02-07 ノバルティス アーゲー Ｐｄ−１に対する抗体分子およびその使用
SG10201601719RA (en) 2016-03-04 2017-10-30 Agency Science Tech & Res Anti-LAG-3 Antibodies
WO2017153952A1 (en) 2016-03-10 2017-09-14 Glaxosmithkline Intellectual Property Development Limited 5-sulfamoyl-2-hydroxybenzamide derivatives
CR20200045A (es) 2016-04-07 2020-03-11 Glaxosmithkline Ip Dev Ltd AMIDAS HETEROCÍCLICAS ÚTILES COMO MODULADORES DE PROTEÍNAS (Divisional 2018-0472)
EP3440072B1 (en) 2016-04-07 2020-01-29 GlaxoSmithKline Intellectual Property Development Ltd Heterocyclic amides useful as protein modulators
EP3452483B1 (en) 2016-05-05 2020-04-01 GlaxoSmithKline Intellectual Property (No. 2) Limited Enhancer of zeste homolog 2 inhibitors
SG10201603721TA (en) 2016-05-10 2017-12-28 Agency Science Tech & Res Anti-CTLA-4 Antibodies
JP7461741B2 (ja) 2016-06-20 2024-04-04 カイマブ・リミテッド 抗ｐｄ－ｌ１およびｉｌ－２サイトカイン
CN109789135A (zh) 2016-07-20 2019-05-21 葛兰素史密斯克莱知识产权发展有限公司 作为perk抑制剂的异喹啉衍生物
EP3494140A1 (en) 2016-08-04 2019-06-12 GlaxoSmithKline Intellectual Property Development Ltd Anti-icos and anti-pd-1 antibody combination therapy
CN109963871A (zh) 2016-08-05 2019-07-02 豪夫迈·罗氏有限公司 具有激动活性的多价及多表位抗体以及使用方法
SG11201900746RA (en) 2016-08-12 2019-02-27 Janssen Biotech Inc Engineered antibodies and other fc-domain containing molecules with enhanced agonism and effector functions
AU2017308734A1 (en) 2016-08-12 2019-02-14 Janssen Biotech, Inc. Fc engineered anti-TNFR superfamily member antibodies having enhanced agonistic activity and methods of using them
WO2018041119A1 (en) 2016-08-31 2018-03-08 Beijing Biocytogen Co., Ltd Genetically modified non-human animal with human or chimeric ox40
CN107815465B (zh) 2016-08-31 2021-03-16 百奥赛图(北京)医药科技股份有限公司 人源化基因改造动物模型的制备方法及应用
TWI788307B (zh) 2016-10-31 2023-01-01 美商艾歐凡斯生物治療公司 用於擴增腫瘤浸潤性淋巴細胞之工程化人造抗原呈現細胞
WO2018083248A1 (en) 2016-11-03 2018-05-11 Kymab Limited Antibodies, combinations comprising antibodies, biomarkers, uses & methods
MA46770A (fr) 2016-11-09 2019-09-18 Agenus Inc Anticorps anti-ox40, anticorps anti-gitr, et leurs procédés d'utilisation
AU2017369994A1 (en) * 2016-12-01 2019-06-13 Glaxosmithkline Intellectual Property Development Limited Combination therapy
KR20190090822A (ko) 2016-12-01 2019-08-02 글락소스미스클라인 인털렉츄얼 프로퍼티 디벨로프먼트 리미티드 조합 요법
SG10201914126RA (en) 2016-12-15 2020-02-27 Abbvie Biotherapeutics Inc Anti-ox40 antibodies and their uses
EA201991207A1 (ru) 2016-12-19 2019-12-30 Гленмарк Фармасьютикалс С.А. Новые агонисты tnfr и их применение
KR20190104048A (ko) 2017-01-06 2019-09-05 이오반스 바이오테라퓨틱스, 인크. 종양 괴사 인자 수용체 슈퍼패밀리 (tnfrsf) 효능제를 사용한 종양 침윤 림프구 (til)의 확장 및 til과 tnfrsf 효능제의 치료 조합물
EP3582855A1 (en) 2017-02-15 2019-12-25 GlaxoSmithKline Intellectual Property Development Limited Combination treatment for cancer
CA3052767A1 (en) 2017-02-27 2018-08-30 Glaxosmithkline Intellectual Property Development Limited Heterocyclic amides as kinase inhibitors
CN108623686A (zh) 2017-03-25 2018-10-09 信达生物制药(苏州)有限公司 抗ox40抗体及其用途
AR112072A1 (es) 2017-06-05 2019-09-18 Iovance Biotherapeutics Inc Métodos de uso de linfocitos infiltrantes de tumor en melanoma doble refractario
EP3635011A1 (en) * 2017-06-09 2020-04-15 GlaxoSmithKline Intellectual Property Development Limited Combination therapy with icos agonist and ox40 agonist to treat cancer
JP2020522556A (ja) 2017-06-09 2020-07-30 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ 癌を治療するためのｉｃｏｓアゴニストおよびｏｘ４０アゴニストでの組み合わせ療法
WO2019021208A1 (en) 2017-07-27 2019-01-31 Glaxosmithkline Intellectual Property Development Limited USEFUL INDAZOLE DERIVATIVES AS PERK INHIBITORS
WO2019053617A1 (en) 2017-09-12 2019-03-21 Glaxosmithkline Intellectual Property Development Limited CHEMICAL COMPOUNDS
AU2018331430A1 (en) 2017-09-13 2020-03-19 Radimmune Therapeutics, Inc. Melanin antibodies and uses thereof
WO2019069270A1 (en) 2017-10-05 2019-04-11 Glaxosmithkline Intellectual Property Development Limited GENERATOR STIMULATOR MODULATORS (STING) INTERFERON
AU2018344902B2 (en) 2017-10-05 2021-06-03 Glaxosmithkline Intellectual Property Development Limited Modulators of stimulator of interferon genes (STING) useful in treating HIV
US11603410B2 (en) 2017-11-01 2023-03-14 Bristol-Myers Squibb Company Immunostimulatory agonistic antibodies for use in treating cancer
SG11202004457XA (en) 2017-11-17 2020-06-29 Iovance Biotherapeutics Inc Til expansion from fine needle aspirates and small biopsies
WO2019106605A1 (en) 2017-12-01 2019-06-06 Board Of Regents, The University Of Texas System Combination treatment for cancer
US11142579B2 (en) 2017-12-06 2021-10-12 Sorrento Therapeutics, Inc. Variant antibodies that bind OX40
TW202116811A (zh) 2017-12-29 2021-05-01 圓祥生命科技股份有限公司 調節免疫檢查點作為癌症治療的單特異性蛋白質、其醫藥組成物、其核酸、及其用途
US11713446B2 (en) 2018-01-08 2023-08-01 Iovance Biotherapeutics, Inc. Processes for generating TIL products enriched for tumor antigen-specific T-cells
WO2019136459A1 (en) 2018-01-08 2019-07-11 Iovance Biotherapeutics, Inc. Processes for generating til products enriched for tumor antigen-specific t-cells
EP3737743A1 (en) 2018-01-08 2020-11-18 Iovance Biotherapeutics, Inc. Processes for generating til products enriched for tumor antigen-specific t-cells
CN111393529B (zh) * 2018-01-29 2022-02-22 康源博创生物科技(北京)有限公司 与ox40l非竞争结合的抗ox40抗体
US20210137930A1 (en) 2018-02-13 2021-05-13 Iovance Biotherapeutics, Inc. Expansion of tumor infiltrating lymphocytes (tils) with adenosine a2a receptor antagonists and therapeutic combinations of tils and adenosine a2a receptor antagonists
TW202003555A (zh) * 2018-03-07 2020-01-16 英商葛蘭素史克智慧財產發展有限公司 用於純化重組多肽之方法
PE20210665A1 (es) 2018-03-23 2021-03-31 Bristol Myers Squibb Co Anticuerpos contra mica y/o micb y sus usos
CN110305210B (zh) 2018-03-27 2023-02-28 信达生物制药(苏州)有限公司 新型抗体分子、其制备方法及其用途
WO2019184909A1 (zh) 2018-03-27 2019-10-03 信达生物制药(苏州)有限公司 新型抗体分子、其制备方法及其用途
BR112020021660A2 (pt) 2018-04-27 2021-02-02 Iovance Biotherapeutics, Inc. métodos para expandir linfócitos infiltrantes de tumor e para tratar um indivíduo com câncer, população de linfócitos infiltrantes de tumor, e, composição de criopreservação
WO2019214624A1 (en) 2018-05-11 2019-11-14 Wuxi Biologics (Shanghai) Co., Ltd. Fully human antibodies against ox40, method for preparing same, and use thereof
GB201807924D0 (en) 2018-05-16 2018-06-27 Ctxt Pty Ltd Compounds
MX2020012567A (es) * 2018-05-23 2021-01-29 Beigene Ltd Anticuerpos anti-ox40 y metodos de uso.
CA3103629A1 (en) 2018-06-15 2019-12-19 Flagship Pioneering Innovations V, Inc. Increasing immune activity through modulation of postcellular signaling factors
WO2020014583A1 (en) 2018-07-13 2020-01-16 Bristol-Myers Squibb Company Ox-40 agonist, pd-1 pathway inhibitor and ctla-4 inhibitor combination for use in a mehtod of treating a cancer or a solid tumor
WO2020030570A1 (en) 2018-08-06 2020-02-13 Glaxosmithkline Intellectual Property Development Limited Combinations of an ox40 antibody and a tlr4 modulator and uses thereof
TW202031273A (zh) 2018-08-31 2020-09-01 美商艾歐凡斯生物治療公司 抗ｐｄ－１抗體難治療性之非小細胞肺癌（ｎｓｃｌｃ）病患的治療
SG11202101787XA (en) 2018-09-20 2021-04-29 Iovance Biotherapeutics Inc Expansion of tils from cryopreserved tumor samples
AU2019347934A1 (en) * 2018-09-26 2021-04-08 Jiangsu Hengrui Medicine Co., Ltd. An anti-OX40 antibody, antigen-binding fragment thereof, and the pharmaceutical use
WO2020077257A1 (en) 2018-10-11 2020-04-16 Inhibrx, Inc. Pd-1 single domain antibodies and therapeutic compositions thereof
BR112021008549A2 (pt) 2018-11-05 2022-01-04 Iovance Biotherapeutics Inc Método de tratamento de carcinoma pulmonar de células não pequenas com uma população de linfócitos infiltrantes de tumor
US20220033775A1 (en) 2018-11-05 2022-02-03 Iovance Biotherapeutics, Inc. Expansion of tils utilizing akt pathways inhibitors
AU2019374761A1 (en) 2018-11-05 2021-06-10 Iovance Biotherapeutics, Inc. Processes for production of tumor infiltrating lymphocytes and uses of the same in immunotherapy
US20230039976A1 (en) 2018-11-05 2023-02-09 Iovance Biotherapeutics, Inc. Selection of improved tumor reactive t-cells
CN113348180B (zh) * 2018-11-20 2023-05-26 上海开拓者生物医药有限公司 Ox40抗体及其制备方法和应用
EP3898949A1 (en) 2018-12-19 2021-10-27 Iovance Biotherapeutics, Inc. Methods of expanding tumor infiltrating lymphocytes using engineered cytokine receptor pairs and uses thereof
US10442866B1 (en) * 2019-01-23 2019-10-15 Beijing Mabworks Biotech Co. Ltd Antibodies binding OX40 and uses thereof
AU2020214412A1 (en) 2019-02-01 2021-08-12 Glaxosmithkline Intellectual Property Development Limited Belantamab mafodotin in combination with pembrolizumab for treating cancer
KR20220002336A (ko) 2019-03-29 2022-01-06 미스트 쎄라퓨틱스, 엘엘씨 T 세포 치료제를 제조하기 위한 생체외 방법 및 관련 조성물 및 방법
EP3962493A2 (en) 2019-05-03 2022-03-09 Flagship Pioneering Innovations V, Inc. Methods of modulating immune activity/level of irf or sting or of treating cancer, comprising the administration of a sting modulator and/or purinergic receptor modulator or postcellular signaling factor
WO2020232029A1 (en) 2019-05-13 2020-11-19 Iovance Biotherapeutics, Inc. Methods and compositions for selecting tumor infiltrating lymphocytes and uses of the same in immunotherapy
EP3969438A1 (en) 2019-05-16 2022-03-23 Stingthera, Inc. Oxoacridinyl acetic acid derivatives and methods of use
US20220251079A1 (en) 2019-05-16 2022-08-11 Stingthera, Inc. Benzo[b][1,8]naphthyridine acetic acid derivatives and methods of use
US20220233691A1 (en) 2019-05-30 2022-07-28 Bristol-Myers Squibb Company Cell localization signature and combination therapy
CN114127315A (zh) 2019-05-30 2022-03-01 百时美施贵宝公司 鉴定适合于免疫肿瘤学(i-o)疗法的受试者的方法
EP3976831A1 (en) 2019-05-30 2022-04-06 Bristol-Myers Squibb Company Multi-tumor gene signatures for suitability to immuno-oncology therapy
CN114222760A (zh) 2019-06-26 2022-03-22 葛兰素史密斯克莱知识产权发展有限公司 Il1rap结合蛋白
GB201910305D0 (en) 2019-07-18 2019-09-04 Ctxt Pty Ltd Compounds
GB201910304D0 (en) 2019-07-18 2019-09-04 Ctxt Pty Ltd Compounds
EP4011389A1 (en) 2019-08-09 2022-06-15 Riken Combined use of artificial adjuvant vector cells and an immunostimulant
WO2021043961A1 (en) 2019-09-06 2021-03-11 Glaxosmithkline Intellectual Property Development Limited Dosing regimen for the treatment of cancer with an anti icos agonistic antibody and chemotherapy
CN114729049A (zh) 2019-09-27 2022-07-08 葛兰素史密斯克莱知识产权发展有限公司 抗原结合蛋白
CA3155727A1 (en) 2019-10-25 2021-04-29 Cecile Chartier-Courtaud Gene editing of tumor infiltrating lymphocytes and uses of same in immunotherapy
WO2021108727A1 (en) 2019-11-27 2021-06-03 Myst Therapeutics, Inc. Method of producing tumor-reactive t cell composition using modulatory agents
EP4073236A1 (en) 2019-12-11 2022-10-19 Iovance Biotherapeutics, Inc. Processes for the production of tumor infiltrating lymphocytes (tils) and methods of using the same
JP2023509359A (ja) 2019-12-17 2023-03-08 フラグシップ パイオニアリング イノベーションズ ブイ，インコーポレーテッド 鉄依存性細胞分解の誘導物質との併用抗癌療法
CN113135994A (zh) * 2020-01-19 2021-07-20 迈威(上海)生物科技股份有限公司 一种激活型抗ox40抗体、生产方法及应用
WO2021152495A1 (en) 2020-01-28 2021-08-05 Glaxosmithkline Intellectual Property Development Limited Combination treatments and uses and methods thereof
EP4110799A1 (en) 2020-02-27 2023-01-04 Myst Therapeutics, LLC Methods for ex vivo enrichment and expansion of tumor reactive t cells and related compositions thereof
EP4146794A1 (en) 2020-05-04 2023-03-15 Iovance Biotherapeutics, Inc. Processes for production of tumor infiltrating lymphocytes and uses of the same in immunotherapy
JP2023524108A (ja) 2020-05-04 2023-06-08 アイオバンス バイオセラピューティクス，インコーポレイテッド 改良された腫瘍反応性ｔ細胞の選択
CN116096906A (zh) 2020-06-29 2023-05-09 旗舰创业创新五公司 工程化以促进萨诺传递的病毒及其在治疗癌症中的用途
CN112442121A (zh) * 2020-08-20 2021-03-05 山东兴瑞生物科技有限公司 Ox40抗体、其编码基因、及抗体的制备方法和在增强人体免疫功能中的应用
WO2022047412A1 (en) 2020-08-31 2022-03-03 Bristol-Myers Squibb Company Cell localization signature and immunotherapy
JP2023546359A (ja) 2020-10-06 2023-11-02 アイオバンス バイオセラピューティクス，インコーポレイテッド 腫瘍浸潤リンパ球療法によるｎｓｃｌｃ患者の治療
WO2022076606A1 (en) 2020-10-06 2022-04-14 Iovance Biotherapeutics, Inc. Treatment of nsclc patients with tumor infiltrating lymphocyte therapies
CA3187272A1 (en) 2020-10-08 2022-04-14 Thorsten Ross Trispecific binders
WO2022120179A1 (en) 2020-12-03 2022-06-09 Bristol-Myers Squibb Company Multi-tumor gene signatures and uses thereof
CA3201818A1 (en) 2020-12-11 2022-06-16 Maria Fardis Treatment of cancer patients with tumor infiltrating lymphocyte therapies in combination with braf inhibitors and/or mek inhibitors
US20240123067A1 (en) 2020-12-17 2024-04-18 Iovance Biotherapeutics, Inc. Treatment of cancers with tumor infiltrating lymphocyte therapies
AU2021401302A1 (en) 2020-12-17 2023-07-06 Iovance Biotherapeutics, Inc. Treatment with tumor infiltrating lymphocyte therapies in combination with ctla-4 and pd-1 inhibitors
WO2022146948A1 (en) 2020-12-28 2022-07-07 Bristol-Myers Squibb Company Subcutaneous administration of pd1/pd-l1 antibodies
IL303648A (en) 2020-12-28 2023-08-01 Bristol Myers Squibb Co Antibody preparations and methods of using them
JP2024505600A (ja) 2021-02-03 2024-02-06 モーツァルト セラピューティクス， インコーポレイテッド 結合剤およびそれを使用する方法
CN112957475B (zh) * 2021-02-04 2022-07-22 李文峰 一种预防和或***的组合物及应用
AU2022230795A1 (en) 2021-03-02 2023-09-21 Glaxosmithkline Intellectual Property Development Limited Substituted pyridines as dnmt1 inhibitors
EP4314060A1 (en) 2021-03-31 2024-02-07 GlaxoSmithKline Intellectual Property Development Limited Antigen binding proteins and combinations thereof
CA3214085A1 (en) 2021-03-31 2022-10-06 Darby Rye Schmidt Thanotransmission polypeptides and their use in treating cancer
EP4314068A1 (en) 2021-04-02 2024-02-07 The Regents Of The University Of California Antibodies against cleaved cdcp1 and uses thereof
BR112023021665A2 (pt) 2021-04-19 2023-12-19 Iovance Biotherapeutics Inc Método para tratar um câncer, e, composição
KR20240026507A (ko) 2021-06-29 2024-02-28 플래그쉽 파이어니어링 이노베이션스 브이, 인크. 타노트랜스미션을 촉진시키도록 엔지니어링된 면역 세포 및 이의 용도
CA3226942A1 (en) 2021-07-28 2023-02-02 Iovance Biotherapeutics, Inc. Treatment of cancer patients with tumor infiltrating lymphocyte therapies in combination with kras inhibitors
CA3216098A1 (en) 2021-07-30 2023-02-02 Uwe Reusch Duplexbodies
CA3232700A1 (en) 2021-09-24 2023-03-30 Rafael CUBAS Expansion processes and agents for tumor infiltrating lymphocytes
WO2023076876A1 (en) 2021-10-26 2023-05-04 Mozart Therapeutics, Inc. Modulation of immune responses to viral vectors
CA3235824A1 (en) 2021-10-27 2023-05-04 Frederick G. Vogt Systems and methods for coordinating manufacturing of cells for patient-specific immunotherapy
WO2023086803A1 (en) 2021-11-10 2023-05-19 Iovance Biotherapeutics, Inc. Methods of expansion treatment utilizing cd8 tumor infiltrating lymphocytes
WO2023147486A1 (en) 2022-01-28 2023-08-03 Iovance Biotherapeutics, Inc. Tumor infiltrating lymphocytes engineered to express payloads
WO2023152116A1 (en) 2022-02-08 2023-08-17 Hookipa Biotech Gmbh Combination therapy with arenavirus particles and immune checkpoint modulators or cytokines
WO2023178192A1 (en) 2022-03-15 2023-09-21 Compugen Ltd. Il-18bp antagonist antibodies and their use in monotherapy and combination therapy in the treatment of cancer
WO2023178329A1 (en) 2022-03-18 2023-09-21 Bristol-Myers Squibb Company Methods of isolating polypeptides
WO2023235847A1 (en) 2022-06-02 2023-12-07 Bristol-Myers Squibb Company Antibody compositions and methods of use thereof
WO2024030758A1 (en) 2022-08-01 2024-02-08 Iovance Biotherapeutics, Inc. Chimeric costimulatory receptors, chemokine receptors, and the use of same in cellular immunotherapies
WO2024054992A1 (en) 2022-09-09 2024-03-14 Bristol-Myers Squibb Company Methods of separating chelator
WO2024056862A1 (en) 2022-09-15 2024-03-21 Avidicure Ip B.V. Multispecific antigen binding proteins for tumor-targeting of nk cells and use thereof
WO2024077191A1 (en) 2022-10-05 2024-04-11 Flagship Pioneering Innovations V, Inc. Nucleic acid molecules encoding trif and additionalpolypeptides and their use in treating cancer

Family Cites Families (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5179017A (en) 1980-02-25 1993-01-12 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4634665A (en) 1980-02-25 1987-01-06 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4510245A (en) 1982-11-18 1985-04-09 Chiron Corporation Adenovirus promoter system
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
US5168062A (en) 1985-01-30 1992-12-01 University Of Iowa Research Foundation Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
US4968615A (en) 1985-12-18 1990-11-06 Ciba-Geigy Corporation Deoxyribonucleic acid segment from a virus
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
DE69233482T2 (de) 1991-05-17 2006-01-12 Merck & Co., Inc. Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen
US6491916B1 (en) 1994-06-01 2002-12-10 Tolerance Therapeutics, Inc. Methods and materials for modulation of the immunosuppresive activity and toxicity of monoclonal antibodies
US5464758A (en) 1993-06-14 1995-11-07 Gossen; Manfred Tight control of gene expression in eucaryotic cells by tetracycline-responsive promoters
US5654168A (en) 1994-07-01 1997-08-05 Basf Aktiengesellschaft Tetracycline-inducible transcriptional activator and tetracycline-regulated transcription units
US6046037A (en) 1994-12-30 2000-04-04 Hiatt; Andrew C. Method for producing immunoglobulins containing protection proteins in plants and their use
ES2315008T5 (es) 1998-02-24 2012-03-06 Sisters Of Providence In Oregon Agente de unión a receptor ox-40 para su uso en métodos de mejora de la respuesta inmune espec�?fica de ant�?geno tumoral.
US6312700B1 (en) 1998-02-24 2001-11-06 Andrew D. Weinberg Method for enhancing an antigen specific immune response with OX-40L
US20020004041A1 (en) * 1999-02-19 2002-01-10 Albert Matthew L. Methods for abrogating a cellular immune response
WO2001064749A2 (en) * 2000-02-28 2001-09-07 Idec Pharmaceuticals Corporation Method for preparing anti-mif antibodies
US7829084B2 (en) 2001-01-17 2010-11-09 Trubion Pharmaceuticals, Inc. Binding constructs and methods for use thereof
US20030186237A1 (en) 2001-02-14 2003-10-02 Baylor College Of Medicine Methods and compositions of amplifying RNA
DK1321477T3 (da) 2001-12-22 2005-02-14 4Antibody Ag Fremgangsmåde til frembringelsen af genetisk modificerede vertebrate precursor-lymfocytter og anvendelse deraf til fremstillingen af heterologe bindende proteiner
AU2002226390B2 (en) 2001-12-22 2007-11-15 4-Antibody Ag Method for the generation of genetically modified vertebrate precursor lymphocytes and use thereof for the production of heterologous binding proteins
AR039209A1 (es) 2002-04-03 2005-02-09 Novartis Ag Derivados de indolilmaleimida
IL164376A0 (en) 2002-04-03 2005-12-18 Applied Research Systems Ox4or binding agents, their preparation and pharmaceutical compositions containing them
DE60317677T2 (de) * 2002-06-13 2008-10-30 Crucell Holland B.V. Ox40 (=cd134) rezeptor agonisten und therapeutische verwendung
EP1578459A3 (en) 2002-10-25 2005-11-23 University of Connecticut Health Center Apparatus and method for immunotherapy of a cancer through controlled cell lysis
US7754209B2 (en) 2003-07-26 2010-07-13 Trubion Pharmaceuticals Binding constructs and methods for use thereof
WO2005013958A1 (en) 2003-08-07 2005-02-17 Novartis Ag Histone deacetylase inhibitors as immunosuppressants
NZ579543A (en) * 2004-07-09 2011-07-29 Chugai Pharmaceutical Co Ltd Anti-glypican 3 antibody
TWI380996B (zh) 2004-09-17 2013-01-01 Hoffmann La Roche 抗ｏｘ４０ｌ抗體
WO2006041763A1 (en) 2004-10-04 2006-04-20 Novartis Ag Renin inhibitors for treating transplantation induced diseases
CA2589802A1 (en) 2004-12-02 2006-06-08 Domantis Limited Plad domain peptides with increased serum half life due to conjugation to domain antibodies
WO2006063067A2 (en) 2004-12-09 2006-06-15 La Jolla Institute For Allergy And Immunology Novel tnf receptor regulatory domain
EP1888639A1 (en) 2005-05-12 2008-02-20 Oncotherapy Science, Inc. Methods for damaging cells using effector function of anti-dsc2 antibody
TWI461436B (zh) * 2005-11-25 2014-11-21 Kyowa Hakko Kirin Co Ltd 人類ｃｄ１３４（ｏｘ４０）之人類單株抗體及其製造及使用方法
AT502823B1 (de) 2005-11-29 2007-06-15 Seitz Alexander Dr Polynukleotid-amplifikation
BRPI0621065A2 (pt) 2005-12-16 2011-11-29 Genentech Inc anticorpo anti-ox40l, anticorpos isolados, polinucleotìdeo, vetor, célula hospedeira, método para fabricar um anticorpo anti-ox40l, método para tratar ou previnir uma disfunção imune, composição e uso de um anticorpo anti-ox40l
WO2007084559A2 (en) 2006-01-13 2007-07-26 Board Of Regents, The University Of Texas System Methods to treat disease states by influencing the signaling of ox40-receptors and high throughput screening methods for identifying substances therefor
US20110008368A1 (en) 2006-01-13 2011-01-13 Board Of Regents, The University Of Texas System Methods of modulating the ox40 receptor to treat cancer
US20120269774A1 (en) 2006-09-21 2012-10-25 Medistem Laboratories, Inc Allogeneic stem cell transplants in non-conditioned recipients
GB0620894D0 (en) 2006-10-20 2006-11-29 Univ Southampton Human immune therapies using a CD27 agonist alone or in combination with other immune modulators
KR20100014588A (ko) 2007-02-27 2010-02-10 제넨테크, 인크. 길항제 ｏｘ40 항체 및 염증성 및 자가면역 질환의 치료에서의 이의 용도
GB0724331D0 (en) 2007-12-13 2008-01-23 Domantis Ltd Compositions for pulmonary delivery
PT2594590E (pt) 2007-12-14 2015-01-14 Bristol Myers Squibb Co Moléculas de ligação ao recetor humano ox40
MA33122B1 (fr) 2009-02-17 2012-03-01 Ucb Pharma Sa Molecules d'anticorps ayant une specificite pour ox40 humain
JP5950824B2 (ja) 2009-12-07 2016-07-13 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー 抗腫瘍抗体療法を増強するための方法
MY171312A (en) 2010-08-23 2019-10-08 Univ Texas Anti-ox40 antibodies and methods of using the same
WO2013008171A1 (en) 2011-07-11 2013-01-17 Glenmark Pharmaceuticals S.A. Antibodies that bind to ox40 and their uses
AU2012299421B2 (en) 2011-08-23 2016-02-04 Board Of Regents, The University Of Texas System Anti-OX40 antibodies and methods of using the same
GB201116092D0 (en) 2011-09-16 2011-11-02 Bioceros B V Antibodies and uses thereof
UA112203C2 (uk) 2011-11-11 2016-08-10 Юсб Фарма С.А. Злитий білок біоспецифічного антитіла, який зв'язується з ox40 людини та сироватковим альбуміном людини
AU2014230741B2 (en) 2013-03-15 2017-04-13 Glaxosmithkline Intellectual Property Development Limited Anti-LAG-3 binding proteins
CN106132439A (zh) * 2014-03-31 2016-11-16 豪夫迈·罗氏有限公司 包含抗血管发生剂和ox40结合激动剂的组合疗法
WO2016059602A2 (en) 2014-10-16 2016-04-21 Glaxo Group Limited Methods of treating cancer and related compositions
KR20180015650A (ko) * 2015-05-07 2018-02-13 아게누스 인코포레이티드 항-ox40 항체 및 이의 사용 방법
MY188049A (en) * 2015-05-29 2021-11-12 Bristol Myers Squibb Co Antibodies against ox40 and uses thereof
EP3582855A1 (en) * 2017-02-15 2019-12-25 GlaxoSmithKline Intellectual Property Development Limited Combination treatment for cancer

Also Published As

Publication number Publication date
US9695246B2 (en) 2017-07-04
EA031849B1 (ru) 2019-03-29
BR112014003982A2 (pt) 2017-05-09
US20150315281A1 (en) 2015-11-05
BR112013004266A2 (pt) 2016-08-02
CN106554417A (zh) 2017-04-05
PE20131403A1 (es) 2014-01-10
IL250691B (en) 2019-05-30
ES2630328T3 (es) 2017-08-21
DK2609118T3 (en) 2017-04-03
US20160068604A1 (en) 2016-03-10
KR20140093600A (ko) 2014-07-28
MX2013002172A (es) 2013-06-28
HUE031371T2 (en) 2017-07-28
ZA201301442B (en) 2014-07-30
EA201390278A1 (ru) 2013-08-30
HK1213272A1 (zh) 2016-06-30
CL2013000545A1 (es) 2014-09-26
NZ716369A (en) 2017-05-26
ME02678B (me) 2017-06-20
KR101704865B1 (ko) 2017-02-09
EP2609118A2 (en) 2013-07-03
JP5984810B2 (ja) 2016-09-06
NZ629913A (en) 2016-01-29
BR112013004266A8 (pt) 2018-01-02
JP6317788B2 (ja) 2018-04-25
PL2609118T3 (pl) 2017-07-31
CO6680693A2 (es) 2013-05-31
CA2809089C (en) 2018-12-18
KR20160149322A (ko) 2016-12-27
LT2609118T (lt) 2017-04-25
MX339964B (es) 2016-06-17
ES2649155T3 (es) 2018-01-10
EA029793B1 (ru) 2018-05-31
US20170267773A1 (en) 2017-09-21
RS55952B1 (sr) 2017-09-29
SG187945A1 (en) 2013-03-28
AU2011293558A1 (en) 2013-03-21
JP2013538057A (ja) 2013-10-10
EP2933268A1 (en) 2015-10-21
HRP20170568T1 (hr) 2017-06-30
WO2012027328A3 (en) 2012-05-31
US20130280275A1 (en) 2013-10-24
WO2012027328A2 (en) 2012-03-01
NZ608033A (en) 2014-09-26
CA2809089A1 (en) 2012-03-01
PE20180042A1 (es) 2018-01-09
JP2017018110A (ja) 2017-01-26
SI2609118T1 (sl) 2017-05-31
KR101719118B1 (ko) 2017-03-22
EP2609118B1 (en) 2017-01-18
EP2609118A4 (en) 2014-03-19
CN103221427A (zh) 2013-07-24
US9006399B2 (en) 2015-04-14
CN106554417B (zh) 2020-11-06
CL2016003052A1 (es) 2017-08-04
US10196450B2 (en) 2019-02-05
US9163085B2 (en) 2015-10-20
US10851173B2 (en) 2020-12-01
AP2013006771A0 (en) 2013-03-31
EA201500204A1 (ru) 2015-11-30
CL2015002526A1 (es) 2016-06-10
IL224886A (en) 2017-11-30
CN103221427B (zh) 2016-08-24
IL250691A0 (en) 2017-04-30
US20190100596A1 (en) 2019-04-04
MY171312A (en) 2019-10-08
EP2933268B1 (en) 2017-07-12
PT2609118T (pt) 2017-03-22
US9527917B2 (en) 2016-12-27
DOP2013000045A (es) 2014-02-28
CR20130126A (es) 2013-06-28
US20140308276A1 (en) 2014-10-16
AU2011293558B2 (en) 2014-07-31

Similar Documents

Publication Publication Date Title
CY1118928T1 (el) Αντι-οχ40 αντισωματα και μεθοδοι χρησης τους
CY1120286T1 (el) Πρωτεϊνες δεσμευσης υποδοχεα προλακτινης και χρησεις αυτων
TN2013000076A1 (en) Anti-ox40 antibodies and methods of using the same
CY1123752T1 (el) Πρωτεϊνες δεσμευσης ιντερλευκινης-13
CY1122676T1 (el) Αντισωματα εναντι της κλαυδινης 18.2 που ειναι χρησιμα στη διαγνωση του καρκινου
CY1122669T1 (el) Σκευασματα αντισωματων αντισκληροστινης υψηλης συγκεντρωσης
CY1121392T1 (el) Μορια δεσμευσης εναντι-αλφα συνουκλεϊνης
CY1123028T1 (el) Σταθερα και διαλυτα αντισωματα που αναστελλουν τον vegf
CY1120471T1 (el) Αντισωματα κατα του cd70
CY1119925T1 (el) Aνti-cd40 αντισωματα, χρησεις και μεθοδοι
CY1119738T1 (el) Ανοσοσυζευγματα αντι-μεσοθηλινης και χρησεις αυτων
EA201590208A1 (ru) Усиление активности т-клеток car путем совместного введения биспецифического антитела
CY1118576T1 (el) Πρωτεϊνες δεσμευομενες με αντιγονο ανθρωπινης il-23
EA201792376A2 (ru) Молекулы анти-gcc антитела и соответствующие композиции и способы
EA201390923A1 (ru) Модифицированное антитело с улучшенным полупериодом существования
AR084210A1 (es) PROTEINAS DE UNION AL TNF-a
BR112012023010A2 (pt) "anticorpo ou fragmento de ligação a antígeno do mesmo que se liga especificamente a cd37, imunoconjugado compreendendo os mesmos, uso dos referidos anticorpo, fragmento e imunoconjugado, composição compreendendo os mesmos, kit, célula isolada, bem como método in vitro para inibir o crescimento de uma célula que expressa cd37"
MY164647A (en) Cea antibodies
IN2014MN00873A (el)
EA201001335A1 (ru) Антитела, направленные против ангиопоэтина-1 и ангиопоэтина-2, и их применение
EA201790664A1 (ru) Антитела против мезотелина и иммуноконъюгаты
EA201171060A1 (ru) Молекулы антител, обладающих специфичностью к человеческому ох40
CY1120326T1 (el) Αντισωματα αντι-ρ-σελεκτινης και μεθοδοι για τη χρηση και την ταυτοποιηση τους
EP2579895A4 (en) ANTI-VEGF ANTIBODIES AND USES THEREOF
EA201101516A1 (ru) Антитела, специфические для кадгерина-17